Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience

G. A. Hale; M. Arora; K. W. Ahn; W. He; B. Camitta; M. R. Bishop; M. Bitan; M. S. Cairo; K. Chan; R. W. Childs; E. Copelan; S. M. Davies; M. A.D. Perez; J. J. Doyle; R. P. Gale; M. G. Vicent; B. N. Horn; A. A. Hussein; S. Jodele; N. R. Kamani; K. A. Kasow; M. Kletzel; H. M. Lazarus; V. A. Lewis; K. C. Myers; R. Olsson; M. Pulsipher; M. Qayed; J. E. Sanders; P. J. Shaw; S. Soni; P. J. Stiff; E. A. Stadtmauer; N. T. Ueno; D. A. Wall; S. A. Grupp

doi:10.1038/bmt.2012.284

Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience

G. A. Hale, M. Arora, K. W. Ahn, W. He, B. Camitta, M. R. Bishop, M. Bitan, M. S. Cairo, K. Chan, R. W. Childs, E. Copelan, S. M. Davies, M. A.D. Perez, J. J. Doyle, R. P. Gale, M. G. Vicent, B. N. Horn, A. A. Hussein, S. Jodele, N. R. KamaniK. A. Kasow, M. Kletzel, H. M. Lazarus, V. A. Lewis, K. C. Myers, R. Olsson, M. Pulsipher, M. Qayed, J. E. Sanders, P. J. Shaw, S. Soni, P. J. Stiff, E. A. Stadtmauer, N. T. Ueno, D. A. Wall, S. A. Grupp

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Although the role of autologous hematopoietic cell transplantation (auto-HCT) is well established in neuroblastoma (NBL), the role of allogeneic HCT (allo-HCT) is controversial. The Center for International Blood and Marrow Transplant Research conducted a retrospective review of 143 allo-HCT for NBL reported in 1990-2007. Patients were categorized into two different groups: those who had not (Group 1) and had (Group 2) undergone a prior auto-HCT (n=46 and 97, respectively). One-year and five-year OS were 59% and 29% for Group 1 and 50% and 7% for Group 2, respectively. Among donor types, disease-free survival (DFS) and OS were significantly lower for unrelated transplants at 1 and 3 years but not at 5 years post HCT. Patients in CR or very good partial response (VGPR) at transplant had lower relapse rates and better DFS and OS, compared with those not in CR or VGPR. Our analysis indicates that allo-HCT can cure some neuroblastoma patients, with lower relapse rates and improved survival in patients without a history of prior auto-HCT as compared with those patients who had previously undergone auto-HCT. Although the data do not address why either strategy was chosen for patients, allo-HCT after a prior auto-HCT appears to offer minimal benefit. Disease recurrence remains the most common cause of treatment failure.

Original language	English (US)
Pages (from-to)	1056-1064
Number of pages	9
Journal	Bone marrow transplantation
Volume	48
Issue number	8
DOIs	https://doi.org/10.1038/bmt.2012.284
State	Published - Aug 2013

Bibliographical note

Funding Information:
The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from Allos, Inc.; Amgen, Inc.; Angioblast; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children’s Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; HistoGenetics, Inc.; Kiadis Pharma; The Leukemia and Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Sanofi; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government.

Keywords

Allogeneic HCT
Autologous HCT
CIBMTR
Neuroblastoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1038/bmt.2012.284

Find It

Find It at U of M Libraries

Cite this

Hale, G. A., Arora, M., Ahn, K. W., He, W., Camitta, B., Bishop, M. R., Bitan, M., Cairo, M. S., Chan, K., Childs, R. W., Copelan, E., Davies, S. M., Perez, M. A. D., Doyle, J. J., Gale, R. P., Vicent, M. G., Horn, B. N., Hussein, A. A., Jodele, S., ... Grupp, S. A. (2013). Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone marrow transplantation, 48(8), 1056-1064. https://doi.org/10.1038/bmt.2012.284

Hale, GA, Arora, M, Ahn, KW, He, W, Camitta, B, Bishop, MR, Bitan, M, Cairo, MS, Chan, K, Childs, RW, Copelan, E, Davies, SM, Perez, MAD, Doyle, JJ, Gale, RP, Vicent, MG, Horn, BN, Hussein, AA, Jodele, S, Kamani, NR, Kasow, KA, Kletzel, M, Lazarus, HM, Lewis, VA, Myers, KC, Olsson, R, Pulsipher, M, Qayed, M, Sanders, JE, Shaw, PJ, Soni, S, Stiff, PJ, Stadtmauer, EA, Ueno, NT, Wall, DA & Grupp, SA 2013, 'Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience', Bone marrow transplantation, vol. 48, no. 8, pp. 1056-1064. https://doi.org/10.1038/bmt.2012.284

@article{89a6363b70134f408da8ec0ba3e88e0a,

title = "Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience",

abstract = "Although the role of autologous hematopoietic cell transplantation (auto-HCT) is well established in neuroblastoma (NBL), the role of allogeneic HCT (allo-HCT) is controversial. The Center for International Blood and Marrow Transplant Research conducted a retrospective review of 143 allo-HCT for NBL reported in 1990-2007. Patients were categorized into two different groups: those who had not (Group 1) and had (Group 2) undergone a prior auto-HCT (n=46 and 97, respectively). One-year and five-year OS were 59% and 29% for Group 1 and 50% and 7% for Group 2, respectively. Among donor types, disease-free survival (DFS) and OS were significantly lower for unrelated transplants at 1 and 3 years but not at 5 years post HCT. Patients in CR or very good partial response (VGPR) at transplant had lower relapse rates and better DFS and OS, compared with those not in CR or VGPR. Our analysis indicates that allo-HCT can cure some neuroblastoma patients, with lower relapse rates and improved survival in patients without a history of prior auto-HCT as compared with those patients who had previously undergone auto-HCT. Although the data do not address why either strategy was chosen for patients, allo-HCT after a prior auto-HCT appears to offer minimal benefit. Disease recurrence remains the most common cause of treatment failure.",

keywords = "Allogeneic HCT, Autologous HCT, CIBMTR, Neuroblastoma",

author = "Hale, {G. A.} and M. Arora and Ahn, {K. W.} and W. He and B. Camitta and Bishop, {M. R.} and M. Bitan and Cairo, {M. S.} and K. Chan and Childs, {R. W.} and E. Copelan and Davies, {S. M.} and Perez, {M. A.D.} and Doyle, {J. J.} and Gale, {R. P.} and Vicent, {M. G.} and Horn, {B. N.} and Hussein, {A. A.} and S. Jodele and Kamani, {N. R.} and Kasow, {K. A.} and M. Kletzel and Lazarus, {H. M.} and Lewis, {V. A.} and Myers, {K. C.} and R. Olsson and M. Pulsipher and M. Qayed and Sanders, {J. E.} and Shaw, {P. J.} and S. Soni and Stiff, {P. J.} and Stadtmauer, {E. A.} and Ueno, {N. T.} and Wall, {D. A.} and Grupp, {S. A.}",

note = "Funding Information: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from Allos, Inc.; Amgen, Inc.; Angioblast; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children{\textquoteright}s Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; HistoGenetics, Inc.; Kiadis Pharma; The Leukemia and Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Sanofi; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government.",

year = "2013",

month = aug,

doi = "10.1038/bmt.2012.284",

language = "English (US)",

volume = "48",

pages = "1056--1064",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation for neuroblastoma

T2 - the CIBMTR experience

AU - Hale, G. A.

AU - Arora, M.

AU - Ahn, K. W.

AU - He, W.

AU - Camitta, B.

AU - Bishop, M. R.

AU - Bitan, M.

AU - Cairo, M. S.

AU - Chan, K.

AU - Childs, R. W.

AU - Copelan, E.

AU - Davies, S. M.

AU - Perez, M. A.D.

AU - Doyle, J. J.

AU - Gale, R. P.

AU - Vicent, M. G.

AU - Horn, B. N.

AU - Hussein, A. A.

AU - Jodele, S.

AU - Kamani, N. R.

AU - Kasow, K. A.

AU - Kletzel, M.

AU - Lazarus, H. M.

AU - Lewis, V. A.

AU - Myers, K. C.

AU - Olsson, R.

AU - Pulsipher, M.

AU - Qayed, M.

AU - Sanders, J. E.

AU - Shaw, P. J.

AU - Soni, S.

AU - Stiff, P. J.

AU - Stadtmauer, E. A.

AU - Ueno, N. T.

AU - Wall, D. A.

AU - Grupp, S. A.

N1 - Funding Information: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from Allos, Inc.; Amgen, Inc.; Angioblast; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children’s Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; HistoGenetics, Inc.; Kiadis Pharma; The Leukemia and Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Sanofi; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government.

PY - 2013/8

Y1 - 2013/8

N2 - Although the role of autologous hematopoietic cell transplantation (auto-HCT) is well established in neuroblastoma (NBL), the role of allogeneic HCT (allo-HCT) is controversial. The Center for International Blood and Marrow Transplant Research conducted a retrospective review of 143 allo-HCT for NBL reported in 1990-2007. Patients were categorized into two different groups: those who had not (Group 1) and had (Group 2) undergone a prior auto-HCT (n=46 and 97, respectively). One-year and five-year OS were 59% and 29% for Group 1 and 50% and 7% for Group 2, respectively. Among donor types, disease-free survival (DFS) and OS were significantly lower for unrelated transplants at 1 and 3 years but not at 5 years post HCT. Patients in CR or very good partial response (VGPR) at transplant had lower relapse rates and better DFS and OS, compared with those not in CR or VGPR. Our analysis indicates that allo-HCT can cure some neuroblastoma patients, with lower relapse rates and improved survival in patients without a history of prior auto-HCT as compared with those patients who had previously undergone auto-HCT. Although the data do not address why either strategy was chosen for patients, allo-HCT after a prior auto-HCT appears to offer minimal benefit. Disease recurrence remains the most common cause of treatment failure.

AB - Although the role of autologous hematopoietic cell transplantation (auto-HCT) is well established in neuroblastoma (NBL), the role of allogeneic HCT (allo-HCT) is controversial. The Center for International Blood and Marrow Transplant Research conducted a retrospective review of 143 allo-HCT for NBL reported in 1990-2007. Patients were categorized into two different groups: those who had not (Group 1) and had (Group 2) undergone a prior auto-HCT (n=46 and 97, respectively). One-year and five-year OS were 59% and 29% for Group 1 and 50% and 7% for Group 2, respectively. Among donor types, disease-free survival (DFS) and OS were significantly lower for unrelated transplants at 1 and 3 years but not at 5 years post HCT. Patients in CR or very good partial response (VGPR) at transplant had lower relapse rates and better DFS and OS, compared with those not in CR or VGPR. Our analysis indicates that allo-HCT can cure some neuroblastoma patients, with lower relapse rates and improved survival in patients without a history of prior auto-HCT as compared with those patients who had previously undergone auto-HCT. Although the data do not address why either strategy was chosen for patients, allo-HCT after a prior auto-HCT appears to offer minimal benefit. Disease recurrence remains the most common cause of treatment failure.

KW - Allogeneic HCT

KW - Autologous HCT

KW - CIBMTR

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=84881369891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881369891&partnerID=8YFLogxK

U2 - 10.1038/bmt.2012.284

DO - 10.1038/bmt.2012.284

M3 - Article

C2 - 23419433

AN - SCOPUS:84881369891

SN - 0268-3369

VL - 48

SP - 1056

EP - 1064

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 8

ER -

Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this